Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Regentis Biomaterials Ltd. (RGNT) had Cash Flow from Financial Activities of $4.42M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$9.29M |
|
$0.03M |
|
$0.06M |
|
$9.35M |
|
$1.65M |
|
-- |
|
$0.02M |
|
$1.67M |
|
$7.68M |
|
$7.68M |
|
$7.68M |
|
7.02M |
|
| Cash Flow Statement Financials | |
$-2.81M |
|
$-0.04M |
|
|
Cash Flow from Financial Activities |
$4.42M |
$7.38M |
|
$8.95M |
|
$1.57M |
|
$0.46M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|